A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Elizabeth M. Burton, Timothy Woody, Isabella Claudia Glitza, Rodabe Navroze Amaria, Emily Zhi-Yun Keung, Adi Diab, Sapna Pradyuman Patel, Michael K.K. Wong, Cassian Yee, Patrick Hwu, Jennifer Leigh McQuade, Scott Eric Woodman, Michael T. Tetzlaff, Michael A. Davies, Jennifer Ann Wargo, Kunal Rai, Hussein Abdul-Hassan Tawbi
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4244062444